Genetic Etiology of Agammaglobulinemia with Absent B Cells

B 细胞缺失的无丙种球蛋白血症的遗传病因学

基本信息

  • 批准号:
    8860110
  • 负责人:
  • 金额:
    $ 36.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-05 至 2015-10-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): E2A is a broadly expressed transcription factor that is essential for early B cell development. The gene for E2A, TCF3, encodes 2 unique basic helix loop helix (bHLH) proteins, E12 and E47, by alternative splicing. Both E12 and E47 can function as homodimers and as heterodimers with each other or with tissue specific transcription factors. Although somatic mutations and translocations involving E2A are seen in leukemias and lymphomas, germline mutations in this gene have not been reported. We have recently identified 4 patients with markedly reduced numbers of B cells and agammaglobulinemia who have exactly the same de novo heterozygous amino acid substitution (E555K) in the basic region of the bHLH domain of E47, the DNA binding segment of the protein. The small number of B cells present in these patients have an unusual phenotype characterized by the increased expression of CD19, a downstream target of E2A, and the absence of a B cell antigen receptor. Bone marrow analysis shows reduced numbers of pro-B cells, increased expression of CD19 and increased tyrosine phosphorylation. Studies with expression vectors indicate that the mutant protein is stable and localizes to the nucleus. The mutation causes a dominant negative effect in electrophoretic mobility shift assays (EMSAs) and luciferase reporters when binding the murine m enhancer. To better understand events that control early B cell development, the proposed studies will examine the functional consequences of the E47 mutation. In Specific Aim 1, we will determine if the E555K mutation in E47 alters its ability to dimerize with essential partners or to bind critical DNA sequences as a homodimer or heterodimer using EMSAs, and chromatin immunoprecipitation (ChIP). The ChIP assays will be done using B cell lines representing various stages of B cell differentiation that have been transfected with E47 wild type or mutant expression vectors. In Specific Aim 2, we will create a knock-in strain of mice with the E555K mutation, and compare these mice with E2A-/- mice and E47-/- mice as well as wild type mice. The number and phenotype of B lineage cells in these mice, the VDJ recombination status and the expression of activation markers will be examined. In Specific Aim 3 we will analyze the functional consequences of mutant E47 in in vivo and in vitro systems. RNA-seq will be used to analyze the alterations in the transcriptome of B cell precursors from wild type versus mutant mice. Regulatory regions of genes identified by ChIP or RNA-seq will be verified by reporter contructs. Finally, transcriptome analysis of common lymphoid precursors from the patients will be performed. The identification of the E555K mutation represents the first autosomal dominant form of agammaglobulinemia. It conforms to recent observations indicating that de novo mutations are not rare and are likely to occur at specific sites in the genome. The results of the proposed studies will enhance our understanding of the requirements for early B cell development and may suggest pathways that be used to treat autoimmune disease and cancer.
描述(由申请人提供):E2 A是一种广泛表达的转录因子,对早期B细胞发育至关重要。E2 A的基因TCF 3通过选择性剪接编码2种独特的碱性螺旋环螺旋(bHLH)蛋白E12和E47。E12和E47都可以作为同源二聚体,也可以作为彼此或与组织特异性转录因子的异源二聚体发挥作用。虽然涉及E2 A的体细胞突变和易位见于白血病和淋巴瘤,但该基因的种系突变尚未报道。我们最近发现了4例B细胞数量明显减少和无丙种球蛋白血症的患者,他们在E47的bHLH结构域(蛋白质的DNA结合片段)的碱性区域具有完全相同的从头杂合氨基酸取代(E555 K)。这些患者中存在的少量B细胞具有不寻常的表型,其特征在于E2 A的下游靶点CD 19的表达增加,并且缺乏B细胞抗原受体。骨髓分析显示前B细胞数量减少,CD 19表达增加和酪氨酸磷酸化增加。表达载体的研究表明,突变蛋白是稳定的,并定位于细胞核。该突变在电泳迁移率变动测定(EMSA)和荧光素酶报告基因中引起显性负效应,当结合鼠m增强子时。为了更好地了解控制早期B细胞发育的事件,拟议的研究将检查E47突变的功能后果。在特定目标1中,我们将确定E47中的E555 K突变是否改变了其与重要伴侣二聚化的能力,或使用EMSA和染色质免疫沉淀(ChIP)将关键DNA序列结合为同源二聚体或异源二聚体的能力。ChIP试验将使用代表B细胞分化各个阶段的B细胞系进行,这些细胞系已用E47野生型或突变表达载体转染。在特定目标2中,我们将创建具有E555 K突变的敲入小鼠品系,并将这些小鼠与E2 A-/-小鼠和E47-/-小鼠以及野生型小鼠进行比较。将检查这些小鼠中B谱系细胞的数量和表型、VDJ重组状态和活化标志物的表达。在具体目标3中,我们将分析突变体E47在体内和体外系统中的功能后果。RNA-seq将用于分析野生型小鼠与突变型小鼠的B细胞前体转录组的改变。通过ChIP或RNA-seq鉴定的基因调控区将通过报告构建体进行验证。最后,将对患者的常见淋巴前体进行转录组分析。E555 K突变的鉴定代表了无丙种球蛋白血症的第一种常染色体显性形式。它符合最近的观察表明,从头突变并不罕见,很可能发生在基因组中的特定位点。拟议的研究结果将增强我们对早期B细胞发育要求的理解,并可能提出用于治疗自身免疫性疾病和癌症的途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MARY ELLEN CONLEY其他文献

MARY ELLEN CONLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MARY ELLEN CONLEY', 18)}}的其他基金

Genetic Etiology of Agammaglobulinemia with Absent B Cells
B 细胞缺失的无丙种球蛋白血症的遗传病因学
  • 批准号:
    8628957
  • 财政年份:
    2014
  • 资助金额:
    $ 36.83万
  • 项目类别:
Clinical Immunology Core
临床免疫学核心
  • 批准号:
    7784223
  • 财政年份:
    2010
  • 资助金额:
    $ 36.83万
  • 项目类别:
NEGATIVE SELECTION AT THE PRO-B TO PRE-B CELL TRANSITION
PRO-B 到 PRE-B 细胞转变时的负选择
  • 批准号:
    6632368
  • 财政年份:
    2001
  • 资助金额:
    $ 36.83万
  • 项目类别:
NEGATIVE SELECTION AT THE PRO-B TO PRE-B CELL TRANSITION
PRO-B 到 PRE-B 细胞转变时的负选择
  • 批准号:
    6511408
  • 财政年份:
    2001
  • 资助金额:
    $ 36.83万
  • 项目类别:
NEGATIVE SELECTION AT THE PRO-B TO PRE-B CELL TRANSITION
PRO-B 到 PRE-B 细胞转变时的负选择
  • 批准号:
    6399793
  • 财政年份:
    2001
  • 资助金额:
    $ 36.83万
  • 项目类别:
GENETIC ASPECTS OF IMMUNODEFICIENCIES
免疫缺陷的遗传方面
  • 批准号:
    2062895
  • 财政年份:
    1987
  • 资助金额:
    $ 36.83万
  • 项目类别:
GENETIC ASPECTS OF IMMUNODEFICIENCIES
免疫缺陷的遗传方面
  • 批准号:
    2330333
  • 财政年份:
    1987
  • 资助金额:
    $ 36.83万
  • 项目类别:
GENETIC ASPECTS OF IMMUNODEFICIENCY
免疫缺陷的遗传方面
  • 批准号:
    3138492
  • 财政年份:
    1987
  • 资助金额:
    $ 36.83万
  • 项目类别:
GENETIC ASPECTS OF IMMUNODEFICIENCIES
免疫缺陷的遗传方面
  • 批准号:
    3138490
  • 财政年份:
    1987
  • 资助金额:
    $ 36.83万
  • 项目类别:
GENETIC ASPECTS OF IMMUNODEFICIENCIES
免疫缺陷的遗传方面
  • 批准号:
    6349782
  • 财政年份:
    1987
  • 资助金额:
    $ 36.83万
  • 项目类别:

相似海外基金

Alternative splicing of Grin1 controls NMDA receptor function in physiological and disease processes
Grin1 的选择性剪接控制生理和疾病过程中的 NMDA 受体功能
  • 批准号:
    488788
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
    Operating Grants
Using proteogenomics to assess the functional impact of alternative splicing events in glioblastoma
使用蛋白质基因组学评估选择性剪接事件对胶质母细胞瘤的功能影响
  • 批准号:
    10577186
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
Long Noncoding RNA H19 Mediating Alternative Splicing in ALD Pathogenesis
长非编码 RNA H19 介导 ALD 发病机制中的选择性剪接
  • 批准号:
    10717440
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
RBFOX2 deregulation promotes pancreatic cancer progression through alternative splicing
RBFOX2 失调通过选择性剪接促进胰腺癌进展
  • 批准号:
    10638347
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
Alternative splicing regulation of CLTC in the heart
心脏中 CLTC 的选择性剪接调节
  • 批准号:
    10749474
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
Nitric oxide as a novel regulator of alternative splicing
一氧化氮作为选择性剪接的新型调节剂
  • 批准号:
    10673458
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
Alternative splicing as an evolutionary driver of phenotypic plasticity
选择性剪接作为表型可塑性的进化驱动力
  • 批准号:
    2884151
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
    Studentship
Rescuing SYNGAP1 haploinsufficiency by redirecting alternative splicing
通过重定向选择性剪接挽救 SYNGAP1 单倍体不足
  • 批准号:
    10660668
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
CAREER: Mechanotransduction, transcription, and alternative splicing in cell biology
职业:细胞生物学中的机械转导、转录和选择性剪接
  • 批准号:
    2239056
  • 财政年份:
    2023
  • 资助金额:
    $ 36.83万
  • 项目类别:
    Continuing Grant
Investigating the role of alternative splicing in the islets of Langerhans in developing diabetes.
研究朗格汉斯岛中选择性剪接在糖尿病发生中的作用。
  • 批准号:
    468851650
  • 财政年份:
    2022
  • 资助金额:
    $ 36.83万
  • 项目类别:
    Research Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了